Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01475331 · ClinicalTrials.gov registry record · Phase 2

The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

A Phase 2 study, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
Phase 2
Development phase
46
Enrollment target

NCT01475331 is a Phase 2 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 46 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01475331, a Phase 2 study, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
46 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the efficacy of a chemotherapeutic cocktail with or without prior ethanol lavage for ablation of premalignant pancreatic cysts using endoscopic ultrasound-guided fine needle injection (EUS-FNI) for agent delivery.

Interventions

  • DRUG Chemotherapy
  • DRUG Ethanol
  • DRUG Normal Saline

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2011-11
Est. Completion 2017-01
Phase Phase 2

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT01475331

The ClinicalTrials.gov registry entry for NCT01475331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Chemotherapy is the first listed.

NCT01475331 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01475331 about?

NCT01475331 is a clinical study titled "The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts". The purpose of this study is to evaluate the efficacy of a chemotherapeutic cocktail with or without prior ethanol lavage for ablation of premalignant pancreatic cysts using endoscopic ultrasound-guided fine needle injection (EUS-FNI) for agent delivery.

What is the current status of trial NCT01475331?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2011-11. Estimated completion is 2017-01.

What interventions are being tested in trial NCT01475331?

The interventions under investigation include: Chemotherapy (DRUG), Ethanol (DRUG), Normal Saline (DRUG).

Who is sponsoring clinical trial NCT01475331?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.